BioCentury
ARTICLE | Clinical News

Acceleron Pharma Inc preclinical data

October 5, 2015 7:00 AM UTC

In mice, twice-weekly 10 mg/kg subcutaneous ACE-2494 increased muscle mass from baseline to week 4 by 40.9% in the rectus femoris, 53.3% in the gastrocnemius and 86.9% in the pectoralis vs. vehicle-tr...